“Conclusion Intravenous paricalcitol significantly increased the percentage of patients at target for the combined endpoint of PTH, calcium , and phosphate (P=0.001).”
“Moreover, between baseline and the second survey, intravenous paricalcitol significantly increased both the percentage of patients at target for PTH (P=0.033) and the percentage of patients at target for the combined endpoint PTH, calcium , and phosphate (P=0.001).”